JP Morgan Chase’s VolitionRx Ltd VNRX Stock Holding History

JP Morgan Chase’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Hold	0	–	-$1	–	7701
2024 Q2	–	Hold	0	–	–	–	7298
2024 Q1	–	Sell	-89	Closed	-$1.28K	–	7923
2023 Q4	$1.28K	Buy	+89	New	+$1.31K	﹤0.01%	6799
2023 Q3	–	Sell	-846	Closed	-$20.9K	–	7419
2023 Q2	$23.5K	Sell	846 -1,050	-55%	-$34.5K	﹤0.01%	5889
2023 Q1	$72K	Buy	+1,896	New	+$79.3K	﹤0.01%	5568
2021 Q3	–	Sell	-1,790	Closed	-$118K	–	6837
2021 Q2	$118K	Sell	1,790 -2,257	-56%	-$153K	﹤0.01%	5487
2021 Q1	$305K	Buy	4,047 +364	+10%	+$31.2K	﹤0.01%	4963
2020 Q4	$286K	Buy	3,683 +2,706	+277%	+$186K	﹤0.01%	4676
2020 Q3	$63K	Buy	977 +15	+2%	+$1.02K	﹤0.01%	4877
2020 Q2	$75K	Buy	+962	New	+$69.5K	﹤0.01%	4675
2020 Q1	–	Sell	-876	Closed	-$83K	–	5758
2019 Q4	$83K	Sell	876 -1,194	-58%	-$124K	﹤0.01%	4963
2019 Q3	$233K	Buy	+2,070	New	+$165K	﹤0.01%	4564

Other funds holding VNRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase's VNRX Position: Q3 2024 in Review

JP Morgan Chase held its VolitionRx Ltd (VNRX) position steady in Q3 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7701.

JP Morgan Chase first reported a position in VNRX in Q3 2019 and has held it in 10 quarters since. The position peaked at $305K in Q1 2021. 22 funds tracked by Wall St. Rank hold VNRX as of Q3 2024.

JP Morgan Chase held 0 shares of VolitionRx Ltd worth $0 as of Q3 2024.
JP Morgan Chase left its VolitionRx Ltd share count unchanged in Q3 2024.
VolitionRx Ltd made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2024, its #7701 holding.
JP Morgan Chase first reported a position in VolitionRx Ltd in Q3 2019 and has held it in 10 quarters since.
JP Morgan Chase's VolitionRx Ltd position peaked at $305K in Q1 2021.
22 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.